Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, has found that a significant proportion of hepatitis C
virus (HCV) patients do not achieve a sustained virologic response or are
not able to tolerate current first-line treatment. According to the new
report entitled Hepatitis C Virus Patient Flow Model and Treatment
Algorithm, although currently available therapies can cure HCV, these
agents are effective in only about half of all patients who receive
therapy. The lack of available efficacious second- and third-line therapies
leads to the accumulation of patients who are non-responsive to first-line
therapy. Because HCV is not a highly fatal disease, this growing population
is awaiting the launch of novel therapies and represents an important
segment in the HCV market.
Hepatitis C virus represents a large commercial opportunity for drug
developers due to its high prevalence, the relatively poor efficacy and
side effects of current therapies and its large undiagnosed and under
treated population.
"A sizeable cohort of the HCV-infected patients is aging, developing
progressive liver disease, and is awaiting the introduction of several
innovative new therapies in late-stage development," said John Lebbos,
M.D., therapeutic area director at Decision Resources. "However, over the
longer term, the size of the candidate population for treatment will be
limited due to the dramatic decreases in the incidence of HCV that have
been achieved as well as the improved efficacy of novel agents."
Based on this report, Decision Resources is offering an exclusive, in
depth webinar entitled Hepatitis C Virus: Forecasting the Drug-Treated and
Treatment Eligible Populations from 2006 to 2021. The webinar, presented by
Dr. Lebbos, will be held at 10 AM (EDT) on September 25, 2007. To register,
visit DecisionResources.
About Hepatitis C Virus Patient Flow Model and Treatment Algorithm
This specialized report includes a detailed, annualized patient
forecast model of the HCV population from 2006 to 2021 which includes the
incidence- and mortality-based model includes estimates of the number of
patients eligible for first-, second-, third, and fourth-line treatment by
genotype and the impact of novel, more effective therapies on the epidemic
and treatment- eligible populations. The HCV patient flow model also allows
the user to adjust key assumptions, providing the model with flexibility to
model different scenarios.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most
extensive claims-based longitudinal patient-level data from PharMetrics(R)
to provide exceptional insight into physicians' prescribing trends and the
factors that drive therapy product choice, from diagnosis through multiple
courses of treatment, for a specific disease.
About Decision Resources
Decision Resources, Inc., (DecisionResources) is a world
leader in healthcare market research publications, advisory services, and
consulting designed to help clients shape strategy, allocate resources, and
master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Decision Resources, Inc.
decisionresources